Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.…
ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
Oncolytics Biotech (NASDAQ: ONCY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 29 employees.
The shares were at 0.3501 USD on 20 November 2026, down 67.6% over 52 weeks. Its 52-week range is 0.3334 USD to 1.300 USD: the price is 73.1% below the high and 5.0% above the low.
Its market capitalisation is 47.66M USD.
Oncolytics Biotech reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.67M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.